Latest news with #SUMMIT
Medscape
a day ago
- Health
- Medscape
Behavioral Activation Therapy Cuts Perinatal Suicide Risk
TOPLINE: In a study of 1117 perinatal adults receiving behavioral activation therapy, the odds of endorsing suicide ideation decreased by 25% with each treatment session and by 80% at 3 months post-randomization, with specialist and nonspecialist providers showing equal effectiveness. METHODOLOGY: A multisite, noninferiority, four-arm randomized clinical trial called the Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) compared clinicians (nonspecialist vs specialist) and modalities (telemedicine vs in-person) in delivering behavioral activation therapy. Research was conducted at university-affiliated networks in Chicago, Illinois; Chapel Hill, North Carolina; and Toronto, Ontario, Canada. Participants included pregnant (≤ 36 weeks) and postpartum (4-30 weeks) adults with depressive symptoms (Edinburgh Postnatal Depression Scale score ≥ 10). A total of 1117 participants who completed at least one treatment session and provided ≥ 1 week of Edinburgh Postnatal Depression Scale data were included in the analysis. Treatment consisted of a manualized 6- to 8-session perinatal behavioral activation intervention delivered weekly. TAKEAWAY: Among 1230 enrolled pregnant and postpartum adults, 1117 completed at least one treatment session, with 264 (23.6%) endorsing suicide ideation during treatment. The odds of endorsing suicide ideation decreased by 25% with each additional treatment session (odds ratio [OR], 0.75; 95% CI, 0.58-0.96; P = .03). At 3 months post-randomization, the odds of endorsing suicide ideation decreased by 80% compared with any time during treatment (OR, 0.20; 95% CI, 0.14-0.27; P < .001). No significant differences were found in the odds of endorsing suicide ideation between clinician types (nonspecialist vs specialist) or delivery modalities (telemedicine vs in person). IN PRACTICE: 'Behavioral activation is a first-line recommended treatment for perinatal depression and may reduce postpartum suicide risk by increasing values-consistent living and awareness of ineffective behaviors,' wrote the authors of the study. SOURCE: The study was led by Parisa Kaliush, PhD, Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, and Daisy Singla, PhD, Centre for Addiction and Mental Health in Toronto. It was published online in JAMA Psychiatry. LIMITATIONS: High suicide risk prompted exclusion from SUMMIT trial, and the final sample was highly educated, suggesting some limitations in generalizability. However, the prevalence of suicide ideation at baseline (15.0%) was higher than previously cited rates. DISCLOSURES: This study was funded by the Patient-Centered Outcomes Research Institute. Bradley Gaynes, PhD, disclosed receiving compensation for authorship/review of UpToDate chapters on depression. Samantha Meltzer-Brody, MD, MPH, reported receiving research funding to the University of North Carolina for clinical trials sponsored by Sage Therapeutics, Electromedical Products International, and Sirtsei Pharmaceuticals, serving as a clinical advisor and professional corporation owner for Modern Health, and serving as a scientific advisor to EmbarkNeuro and Seaport Therapeutics. Simone Vigod, MD, disclosed receiving royalties from UpToDate for authorship of materials on depression and pregnancy. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Business Wire
17-06-2025
- Business
- Business Wire
The Women in Manufacturing Association Announces 15 th Annual SUMMIT in Chicago
CLEVELAND, Ohio--(BUSINESS WIRE)--The Women in Manufacturing Association (WiM) is excited to announce its 15th annual WiM SUMMIT, taking place October 12–14, 2025, at McCormick Place in Chicago, IL. This milestone conference is expected to welcome more than 2,500 in-person and virtual attendees from across the global manufacturing sector for three days of community-building, leadership development, and industry celebration. As we mark 15 years of building a more inclusive industry, we look forward to gathering with the WiM community to honor progress, recognize excellence, and spark the ideas that will shape the next generation of manufacturing leaders. Share With the inspiring theme 'Make Your Mark,' this year's WiM SUMMIT will focus on the influence of purposeful leadership, courageous innovation and the importance of leaving a legacy in manufacturing. Attendees will engage in meaningful programming designed to motivate, educate and connect professionals at all career stages and sectors within manufacturing. 'This year's theme is a powerful reflection of where we've been and where we're going,' said Allison Grealis, WiM President and Founder. 'As we mark 15 years of building a more inclusive industry, we look forward to gathering with the WiM community to honor progress, recognize excellence, and spark the ideas that will shape the next generation of manufacturing leaders.' WiM SUMMIT 2025 highlights include: Keynote speakers representing General Mills, the National Women's History Museum, and Disney Institute, sharing insights on leadership, the multigenerational workforce, and igniting purpose in those who are the future of manufacturing. An opening keynote on authenticity given by Caroline Wanga, Co-Founder of WangaWoman and President & CEO of Essence Ventures. More than 65 educational sessions and workshops on topics critical to the industry, including allyship, professional development, manufacturing business trends, strategic leadership, sustainability, transformational innovation and more. The WiM EXPO, an interactive exhibition hall featuring best-in-class manufacturers showcasing their commitment to innovation and excellence. Signature networking and social events, providing opportunities for professionals to connect across sectors and experience the vibrant culture of Chicago. In addition to the educational and networking offerings, the 2025 SUMMIT will celebrate exceptional individuals who have made a lasting impact on the industry. WiM will induct its newest class into the Women in Manufacturing Hall of Fame and recognize the 2025 Bill Gaskin Ally Award recipient, honoring those who have championed equity and opportunity for women in manufacturing. Since 2010, WiM has grown into the leading global trade association dedicated to supporting, promoting, and inspiring women and allies in the manufacturing industry. The WiM SUMMIT remains the association's flagship event, offering an unmatched platform for professional development and industry recognition. Registration for WiM SUMMIT 2025 is now open. Discounted rates are available for groups of six or more. Visit the WiM SUMMIT website to explore the agenda, speaker lineup, travel information and registration options. Contact meetings@ for more information. The Women in Manufacturing Association (WiM) is a global trade association dedicated to supporting, promoting and inspiring women who have chosen a career in the manufacturing industry. It provides year-round support to more than 33,000 individual members representing more than 3,000 manufacturing companies from 50 U.S. states and more than 75 countries. WiM encompasses manufacturers of all types and welcomes individuals from every job function – from production to the C-Suite. Membership is available to anyone working within or with the manufacturing sector.
Yahoo
02-04-2025
- Health
- Yahoo
ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
At the American College of Cardiology's 74th Annual Scientific Session in Chicago, further results and analyses were presented from the SUMMIT trial. SUMMIT was the first trial in patients with heart failure with preserved ejection fraction (HFpEF) and obesity with heart failure outcomes as the primary prespecified endpoint. The trial examined the effect of Eli Lilly's glucagon-like peptide-1 receptor agonist (GLP-1RA) tirzepatide, which is marketed as Mounjaro, on the clinical trajectory of patients with HFpEF and obesity. The study had previously identified that tirzepatide was able to reduce the composite of cardiovascular (CV) death and worsening HF events by 38% (P=0.026), an effect that was consistent across various definitions of events. Obesity often leads to both HFpEF and chronic kidney disease (CKD); CKD may influence the clinical course of obesity-related HFpEF, and incretin-based drugs may influence renal function. This study had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function. Key opinion leaders (KOLs) interviewed by GlobalData have often commented on the need for a therapy that can achieve a broader cardiometabolic approach in treating disease such as CV-kidney metabolic syndrome, which the SUMMIT trial investigates, and tirzepatide's success in treating this broader metabolic syndrome is likely to achieve favourable opinion and uptake from physicians. The SUMMIT trial randomly assigned 731 patients with HFpEF: chronic HF, left ventricular failure (LVEF) 50% or higher, and body mass index at or above 30kg/m2. Patients were also required to have one of the following: 1) left atrial enlargement; 2) elevated left ventricular (LV) pressures; or 3) NT-proBNP greater than 200pg/mL in sinus rhythm or greater than 600pg/mL in AF. Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks. Because of the confounding variables produced by obesity, and changes in muscle mass, estimated glomerular filtration rate (eGFR) was assessed at the point of randomisation and after 12, 24, and 52 weeks by both creatinine-based and cystatin C–based eGFR calculation formulae. The enrichment criteria used to identify participants at high risk of events included: 6 minute walk test (6MWT) ≥100 and ≤425 meters, KCCQ-CSS ≤80 and HF decompensation within 12 months or eGFR <70m/min/1.73m2. If they met these criteria, participants were then randomised for the duration of double-treatment and follow-up. Patients were on a starting dose of 2.5mg/week, which was uptitrated by 2.5mg every four weeks, as tolerated, until it reached 15mg/week by 20 weeks, and the double-blind treatment was maintained until the last patient completed 52 weeks. Patients with CKD (based on creatinine or cystatin C) had greater severity of heart failure, as reflected by: 1) worse functional class, KCCQ-CSS scores, and 6-minute walk distance; 2) higher levels of NT-proBNP and cardiac troponin T; and 3) a two-fold increase in the risk of worsening heart failure events. CKD did not influence the effect of tirzepatide to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity, but the absolute risk reduction in the primary events was numerically greater in patients with CKD. Regarding renal function assessments, baseline eGFR-cystatin C was consistently approximately 9mL/min/1.73m2 lower than that of eGFR-creatinine, with significant individual variance. Furthermore, tirzepatide increased eGFR at 52 weeks, assessed by both creatinine-based and cystatin C–based formulae, but with considerable discordance in individual patients. Tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine (but not eGFR-cystatin C), and it led to an improvement in eGFR at 52 weeks in all patients (when assessed by cystatin C), but only in patients with CKD (when assessed by eGFR-creatinine). This substudy from the SUMMIT trial demonstrates long-term tirzepatide improves renal function (both by cystatin C and creatinine), but the measurement of eGFR in patients with obesity receiving GLP-1RAs is likely to be skewed by the effects of fat and muscle mass and the changes in body composition on the synthesis of both cystatin C and creatinine. GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease and beyond the traditional prescribing of GLP-1RAs for type 2 diabetes (T2D), steadily becoming one of the leading GLP-1 therapies in the market. "ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
